.
MergerLinks Header Logo

New Deal


Announced

Mycotopia to acquire Ei.Ventures for $382m.

Financials

Edit Data
Transaction Value£288m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Private

Pending

psilocybin

Majority

psychedelics

Friendly

Single Bidder

Domestic

Acquisition

Pharmaceuticals

Synopsis

Edit

Mycotopia, a biopharma company focused on research, technology, and the development of medical psychedelics, agreed to acquire Ei.Ventures, a botanical psilocybin pioneer, for $382m. "I am excited by the amount of wisdom these two companies could bring together. Everyone in these companies has a background in public markets, a decade plus in cannabis, and lawyers that have been involved in cannabis legislation, as well as start-ups, and heavily compliance-oriented businesses. We were the first to work on legally-compliant CBD products, and we were the first to work on a commercial Ayurvedic spa in the US built around plant medicine. Between Benny, Jason and myself we’ve invested in more than 100 companies. This is not our first rodeo. That’s what makes this a real Olympic team, ‘A’ players only," David Nikzad, Ei.Ventures Founder and Chairman.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US